Amendment: SEC Form SC 13D/A filed by Immunome Inc.

     

Explanatory Note

This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D relates to shares of common stock, par value $0.0001 per share (“Common Stock”), of Immunome, Inc., a Delaware corporation (the “Issuer”), and amends and supplements the initial statement on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) by the Reporting Persons on October 12, 2023 (the “Original Schedule 13D,” and as amended by Amendment No. 1, the “Schedule 13D”). Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Original Schedule 13D.

  

Item 2.  Identity and Background.

Item 2 of the Schedule 13D is hereby amended and restated to read as follows:

(a)  This Statement is being filed by:

1.	Arsenal Bridge Venture II, LLC, a Delaware limited liability company (“ABV II”),

2.	Arsenal Bridge Venture II-B, LLC, a Delaware limited liability company (“ABV II-B”),

3.	Arsenal Bridge Advisors, LLC, a Delaware limited liability company (the “Investment Adviser”)

4.	RBP Catalyst Fund, L.P., a Delaware limited partnership (“RBP Catalyst”),

5.	Research Bridge Partners, Inc., a Delaware corporation (“RBP”),

6.	Isaac Barchas, and

7.	James Graham (collectively, the “Reporting Persons”).

Each of ABV II, ABV II-B, RBP Catalyst, RBP and Isaac Barchas is the record and direct beneficial owner of the shares of Common Stock covered by this Statement.

The Investment Adviser is the investment adviser of ABV II and ABV II-B and may be deemed to beneficially own securities owned by ABV II and ABV II-B pursuant to a power of attorney from ABHMC II, LLC, the managing member of ABV II and ABV II-B. Each of Isaac Barchas and James Graham may be deemed to beneficially own securities owned by ABV II and ABV II-B.

RBP is the general partner of RBP Catalyst and may be deemed to beneficially own securities owned by RBP Catalyst. Mr. Barchas was previously the Chief Executive Officer of RBP and exercised voting and investment power over the shares owned by RBP and RBP Catalyst, and therefore may have been deemed to beneficially own securities owned RBP and RBP Catalyst. On January 1, 2024, Mr. Barchas resigned as Chief Executive Officer of RBP and no longer exercises voting and investment power over the shares owned by RBP and RBP Catalyst. RBP and RBP Catalyst are no longer members of the Schedule 13(d) group and shall cease to be Reporting Persons immediately upon filing of this Amendment No. 1.

 

(b)  The address of the principal business office of each Reporting Person is 1807 W. 11th Street, Austin, Texas, 78703.

	Arsenal Bridge Venture II, LLC
	By:	ABHMC II, LLC, its Managing Member
	By:	/s/ Isaac Barchas
	Name:	Isaac Barchas
	Title:	Managing Member